Skip to main content
Premium Trial:

Request an Annual Quote

Does Cancer Lie About its Age on its Driver's License?

Premium

A diagnosis of pancreatic cancer — with its prognosis of a 5 percent chance of survival for five years — is enough to shake even the most stoic of patients. But there is now evidence that shows that pancreatic cancer mutations begin developing 15 years before most people are diagnosed, says Melinda Wenner Moyer at Scientific American, indicating that there may be "plenty of time for doctors to intervene." In a letter published in Nature, a group of researchers from Johns Hopkins University say that they sequenced the genomes of seven patients who died from late-stage pancreatic cancer and, tracing the evolution of their mutations, found that they could be tracked back 10 years before cancer cells actually started to develop. Other researchers are working on screening techniques for pancreatic cancer, Moyer says, with one group identifying cancer-related RNAs in patients' saliva, and another group developing an optical technology that recognizes various stages of pancreatic cancer cells. Those technologies are still being developed but they are expected to advance in the next decade, she reports.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.